Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Core Insights - Nyxoah will participate in the Oppenheimer 35 Annual Healthcare MedTech & Services Conference from March 17 to 20, 2025 [1] - CEO Olivier Taelman will present on March 17, 2025, at 8:40am ET, with a webcast available for investors [2] - The company focuses on innovative treatments for Obstructive Sleep Apnea (OSA) through neuromodulation [3] Company Overview - Nyxoah develops breakthrough treatment alternatives for OSA, with its first product being the Genio® device, which is battery-free and inserted through a single incision [3] - The Genio® system received its European CE Mark in 2019 after the successful BLAST OSA study [4] - The company has completed two IPOs, one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021 [4] - Following positive outcomes from the BETTER SLEEP study, Nyxoah expanded its therapeutic indications to include Complete Concentric Collapse (CCC) patients [4] - The company also announced positive results from the DREAM IDE pivotal study, which is aimed at FDA and U.S. commercialization approval [4]